This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Xipamide is a diuretic indicated in the treatment of edema.

Generic Name
Xipamide
DrugBank Accession Number
DB13803
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 354.81
Monoisotopic: 354.0441058
Chemical Formula
C15H15ClN2O4S
Synonyms
  • Xipamida
  • Xipamide
  • Xipamidum
External IDs
  • BE 1293
  • BE-1293
  • MJF 10,938
  • MJF 10938

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirXipamide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Xipamide.
AcebutololAcebutolol may increase the hypotensive activities of Xipamide.
AceclofenacThe therapeutic efficacy of Xipamide can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Xipamide can be decreased when used in combination with Acemetacin.
AcetaminophenXipamide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Xipamide.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Xipamide which could result in a higher serum level.
AclidiniumXipamide may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
AcrivastineXipamide may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
NEOTRIXipamide (10 mg) + Triamterene (30 mg)Tablet, film coatedOral2006-07-01Not applicableGermany flag
NEOTRIXipamide (10 mg) + Triamterene (30 mg)Tablet, film coatedOral2006-07-012020-10-15Germany flag
NEOTRIXipamide (10 mg) + Triamterene (30 mg)Tablet, film coatedOral2006-07-012020-10-15Germany flag

Categories

ATC Codes
C03BA10 — Xipamide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
4-halobenzoic acids and derivatives / Benzenesulfonamides / Salicylamides / Benzamides / Benzenesulfonyl compounds / m-Xylenes / Benzoyl derivatives / M-chlorophenols / Chlorobenzenes / 1-hydroxy-2-unsubstituted benzenoids
show 11 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / 3-chlorophenol / 3-halophenol / 4-halobenzoic acid or derivatives / Aminosulfonyl compound / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Benzamide / Benzanilide
show 30 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
4S9EY0NUEC
CAS number
14293-44-8
InChI Key
MTZBBNMLMNBNJL-UHFFFAOYSA-N
InChI
InChI=1S/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)
IUPAC Name
4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy-5-sulfamoylbenzamide
SMILES
CC1=CC=CC(C)=C1NC(=O)C1=CC(=C(Cl)C=C1O)S(N)(=O)=O

References

General References
  1. DIMDI Product Information: NEOTRI (xipamide and triamterene) oral tablet [Link]
ChemSpider
24795
RxNav
11371
ChEBI
135499
ChEMBL
CHEMBL517199
ZINC
ZINC000000538538
Wikipedia
Xipamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentArousal Disorders, Sexual / Female Sexual Dysfunction (FSD) / Genito-Pelvic Pain/Penetration Disorder / Painful Intercourse / Postmenopausal Syndrome / Sexual Pain Disorders / Sexual; Disorder, Arousal, Female / Vestibulodynia / Vulvo Vaginal Atrophy / Vulvodynia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
TabletOral40 mg
Tablet, film coatedOral
TabletOral10 MG
TabletOral20 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0246 mg/mLALOGPS
logP2.73ALOGPS
logP3ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)6.17ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area109.49 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity90.62 m3·mol-1ChemAxon
Polarizability34.43 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:48 / Updated at May 21, 2021 10:23